2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Clinical Procedures, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Quality of Care, Diseases, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Immunology, GVHD, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Animal Model
PAPER

2461 Post-transplant cyclophosphamide and calcineurin inhibitor with or without mycophenolate mofetil for graft-versus-host disease prophylaxis in haploidentical HCT for acute myeloid leukemia: A study from the acute leukemia working party of the European society for blood and marrow transplantation

Jia Chen Sr, MD, Yuhua Ru2, Thibeault Ferhat Berland, PhD3, Raynier Devillier, PhD4, Emanuele Angelucci, MD5, Stefania Bramanti6, Mi Kwon   , MD, PhD7, Fabio Ciceri, MD8, Lucia Lopez Corral, MD, PhD9, Simona Sica, MD, PhD10, Maija Itälä-Remes11, Massimo Martino12, Jane Felicity Apperley, FRCP, FRCPath, MB13, Depei Wu Sr, MD14, Mohamad Mohty, MD, PhD15, Norbert Claude Gorin, MD, PhD16, Alexandros Spyridonidis17, Francesco Saraceni18, Frederic Baron19, Jaime Sanz, MD, PhD20, Arnon Nagler I, MD21, Eolia Brissot, MD, PhD22
1 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China
2 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China
3 EBMT Paris Office, Hôpital Saint-Antoine, AP-HP, Sorbonne University, Paris, France
4 Institut Paoli-Calmettes, Aix-Marseille Université, Marseille, France
5 UO Ematologia e Terapie Cellulari, AOM-IRCCS Ospedale Policlinico San Martino, Genova, Italy
6 Bone Marrow Transplantation and Cell Therapy Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
7 Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
8 IRCCS Ospedale San Raffaele, Milan, Italy
9 Hospital Clínico, Salamanca, Spain
10 Fondazione Policlinico Universitario Agostino Gemelli IRCCS, and Università Cattolica del Sacro Cuore, Rome, Italy
11 Turku University Hospital, Turku, Finland
12 Grande Ospedale Metropolitano Bianchi Melacrino Morelli - Centro Unico Trapianti A. Neri, Reggio Calabria, Italy
13 Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom
14 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China
15 EBMT Paris Office, Hôpital Saint-Antoine, AP-HP, Sorbonne University, Paris, France
16 EBMT Paris Office, Hôpital Saint-Antoine, AP-HP, Sorbonne University, Paris, France
17 University Hospital of Patras, University of Patras, Patras, Greece
18 Ospedali Riuniti di Ancona, Ancona, Italy
19 CHU of Liège and University of Liège, Liège, Belgium
20 Hospital Universitari i Politècnic La Fe, Valencia, Spain
21 Chaim Sheba Medical Center, Tel Hashomer, and Tel Aviv University, Tel Aviv, Israel
22 EBMT Paris Office, Hôpital Saint-Antoine, AP-HP, Sorbonne University, Paris, France

Introduction

Post-transplant cyclophosphamide (PTCy) combined with a calcineurin inhibitor (CNI) and mycophenolate mofetil (MMF) is widely used for graft-versus-host disease (GVHD) prophylaxis after haploidentical hematopoietic cell transplantation (HCT). However, delayed hematopoietic recovery and infectious complications remain important limitations of haploidentical HCT, and MMF may contribute to delayed engraftment and excessive immunosuppressive burden. Whether MMF provides additional GVHD protection when PTCy and a CNI are already administered remains uncertain. Therefore, we compared PTCy+CNI+MMF with PTCy+CNI in adults with acute myeloid leukemia (AML) undergoing haploidentical HCT in first complete remission (CR1).

 

Methods

We retrospectively analyzed adult patients (≥18 years) with AML in CR1 who underwent their first allogeneic HCT between 2010 and 2023 from a haploidentical donor using peripheral blood (PB) or bone marrow (BM) grafts. Patients received PTCy+CNI with or without MMF for GVHD prophylaxis. Propensity score matching at a 3:1 ratio with a caliper of 0.2 was used to balance the cohorts for age and year at HCT, Karnofsky performance status (KPS) score, conditioning intensity, female donor–male recipient combination, graft source, and donor-recipient cytomegalovirus (CMV) serostatus. Data were reported to the European Society for Blood and Marrow Transplantation.

 

Results

The study included 2,885 patients, with 2,718 (94%) receiving PTCy+CNI+MMF and 167 receiving PTCy+CNI without MMF. Patients receiving PTCy+CNI+MMF were transplanted more recently than those receiving PTCy+CNI (median year, 2020 vs. 2019; P=0.026) and tended to have a higher rate of recipient CMV seropositivity (78.4% vs. 72.1%; P=0.057). The groups did not differ significantly in patient or donor sex or age, KPS, graft source, conditioning intensity, European LeukemiaNet 2022 cytogenetic risk classification, female donor–male recipient combination, donor CMV serostatus, or donor–recipient CMV serostatus.

 

Median follow-up was 3.5 years in the PTCy+CNI+MMF group and 4.1 years in the PTCy+CNI group. At 2 years, overall survival (OS) was 66.0% in the PTCy+CNI+MMF group and 62.7% in the PTCy+CNI group. Leukemia-free survival (LFS) was 60.9% and 56.1%, graft-versus-host disease (GVHD)-free, relapse-free survival (GRFS) was 49.5% and 47.6%, relapse incidence (RI) was 19.3% and 20.2%, and non-relapse mortality (NRM) was 19.8% and 23.7%, respectively. In the PTCy+CNI+MMF and PTCy+CNI groups, the 180-day cumulative incidences of grade II–IV acute GVHD (aGVHD) were 32.4% and 33.1%, respectively, and the 180-day cumulative incidences of grade III–IV aGVHD were 11.7% in both groups. The 2-year cumulative incidences of chronic GVHD (cGVHD) were 32.4% and 35.2%, while the 2-year cumulative incidences of extensive cGVHD were 5.2% and 6.4%, respectively. Neutrophil recovery by day 30 was 91.3% and 96.2%, and platelet recovery by day 60 was 86.6% and 86.5%, respectively.

 

In multivariable analysis, with the MMF group as the reference, no significant differences were observed in OS (hazard ratio [HR], 1.12; 95% CI, 0.85–1.46; P=0.431), LFS (HR, 1.08; 95% CI, 0.84–1.40; P=0.538), GRFS (HR, 0.99; 95% CI, 0.77–1.28; P=0.962), RI (HR, 1.01; 95% CI, 0.70–1.47; P=0.953), or NRM (HR, 1.15; 95% CI, 0.81–1.63; P=0.441). No significant differences were observed in grade II–IV aGVHD (HR, 1.04; P=0.822), grade III–IV aGVHD (HR, 0.93; P=0.785), cGVHD (HR, 1.06; P=0.747), or extensive cGVHD (HR, 1.07; P=0.863).

 

After propensity score matching, 615 patients were included, comprising 461 in the PTCy+CNI+MMF group and 154 in the PTCy+CNI group. The results were consistent with the multivariable analysis, with no significant differences in OS, LFS, GRFS, RI, NRM, GVHD outcomes, or neutrophil recovery.

 

Conclusion

In patients undergoing haploidentical HCT for AML in CR1, outcomes of OS, LFS, GRFS, RI, NRM, GVHD and hematopoietic recovery were similar between PTCy+CNI with and without MMF. These findings if confirmed may suggest that MMF may be omitted from PTCy/CNI/MMF prophylaxis without apparent compromise in GVHD control or engraftment and further support prospective investigation of a simplified PTCy/CNI regimen.

Jia Chen Sr, MD: No relevant conflicts of interest to declare.